FWIW, its in research note from Friday, Wilsons seem to have been in touch with Clarity management and state:
"For reference, at this stageClarity expect to dose 4 cycles of 12 GBq, in a pivotal trial, and therefore the upcoming Cohort 4data (12+12GBq dosing) will be the most meaningful as to guiding to future efficacy."
So seems like there is already an idea about dosing in the pivotal trial unless Cohort 4 produces something out of left field.
FWIW, its in research note from Friday, Wilsons seem to have...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.65 |
Change
0.380(11.6%) |
Mkt cap ! $1.134B | |||
| Open | High | Low | Value | Volume |
| $3.30 | $3.75 | $3.29 | $15.67M | 4.533M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6405 | $3.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.65 | 13893 | 3 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$3.65 |
Change
0.380 ( 11.9 %) |
||||
| Open | High | Low | Volume | ||
| $3.29 | $3.76 | $3.29 | 345059 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| CU6 (ASX) Chart |